Literature DB >> 24430180

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.

Nuray Gül, Liane Babes, Kerstin Siegmund, Rianne Korthouwer, Marijn Bögels, Rens Braster, Gestur Vidarsson, Timo L M ten Hagen, Paul Kubes, Marjolein van Egmond.   

Abstract

The use of monoclonal antibodies (mAbs) as therapeutic tools has increased dramatically in the last decade and is now one of the mainstream strategies to treat cancer. Nonetheless, it is still not completely understood how mAbs mediate tumor cell elimination or the effector cells that are involved. Using intravital microscopy, we found that antibody-dependent phagocytosis (ADPh) by macrophages is a prominent mechanism for removal of tumor cells from the circulation in a murine tumor cell opsonization model. Tumor cells were rapidly recognized and arrested by liver macrophages (Kupffer cells). In the absence of mAbs, Kupffer cells sampled tumor cells; however, this sampling was not sufficient for elimination. By contrast, antitumor mAb treatment resulted in rapid phagocytosis of tumor cells by Kupffer cells that was dependent on the high-affinity IgG-binding Fc receptor (FcγRI) and the low-affinity IgG-binding Fc receptor (FcγRIV). Uptake and intracellular degradation were independent of reactive oxygen or nitrogen species production. Importantly, ADPh prevented the development of liver metastases. Tumor cell capture and therapeutic efficacy were lost after Kupffer cell depletion. Our data indicate that macrophages play a prominent role in mAb-mediated eradication of tumor cells. These findings may help to optimize mAb therapeutic strategies for patients with cancer by helping us to aim to enhance macrophage recruitment and activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24430180      PMCID: PMC3904600          DOI: 10.1172/JCI66776

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Surgery-induced reactive oxygen species enhance colon carcinoma cell binding by disrupting the liver endothelial cell lining.

Authors:  Nuray Gül; Marijn Bögels; Simran Grewal; Anne Jan van der Meer; Lucy Baldeon Rojas; Donna M Fluitsma; M Petrousjka van den Tol; Kees A Hoeben; Jan van Marle; Helga E de Vries; Robert H J Beelen; Marjolein van Egmond
Journal:  Gut       Date:  2011-01-27       Impact factor: 23.059

2.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

3.  Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.

Authors:  Ezogelin Oflazoglu; Ivan J Stone; Kristine A Gordon; Iqbal S Grewal; Nico van Rooijen; Che-Leung Law; Hans-Peter Gerber
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

Review 4.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

5.  Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy.

Authors:  Gerben J van der Bij; Marijn Bögels; Marielle A Otten; Steven J Oosterling; Peter J Kuppen; Sybren Meijer; Robert H J Beelen; Marjolein van Egmond
Journal:  J Hepatol       Date:  2010-06-17       Impact factor: 25.083

Review 6.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Authors:  P Mark Hogarth; Geoffrey A Pietersz
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

7.  Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.

Authors:  Pascale Hubert; Adèle Heitzmann; Sophie Viel; André Nicolas; Xavier Sastre-Garau; Pablo Oppezzo; Otto Pritsch; Eduardo Osinaga; Sebastian Amigorena
Journal:  Cancer Res       Date:  2011-06-22       Impact factor: 12.701

Review 8.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications.

Authors:  N Van Rooijen; A Sanders
Journal:  J Immunol Methods       Date:  1994-09-14       Impact factor: 2.303

Review 9.  Determination of immunomodulatory effects: focus on functional analysis of phagocytes as representatives of the innate immune system.

Authors:  Ursula Bilitewski
Journal:  Anal Bioanal Chem       Date:  2008-04-22       Impact factor: 4.142

10.  Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40.

Authors:  E Oflazoglu; I J Stone; L Brown; K A Gordon; N van Rooijen; M Jonas; C-L Law; I S Grewal; H-P Gerber
Journal:  Br J Cancer       Date:  2008-12-09       Impact factor: 7.640

View more
  116 in total

1.  Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.

Authors:  Jonathan J Pinney; Fátima Rivera-Escalera; Charles C Chu; Hannah E Whitehead; Karl R VanDerMeid; Ashley M Nelson; Michelle C Barbeau; Clive S Zent; Michael R Elliott
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

2.  Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Authors:  Kirstie L S Cleary; H T Claude Chan; Sonja James; Martin J Glennie; Mark S Cragg
Journal:  J Immunol       Date:  2017-04-12       Impact factor: 5.422

3.  Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.

Authors:  Young-Chan Kwon; Hangeun Kim; Keith Meyer; Adrian M Di Bisceglie; Ranjit Ray
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

Review 4.  The emerging molecular machinery and therapeutic targets of metastasis.

Authors:  Yutong Sun; Li Ma
Journal:  Trends Pharmacol Sci       Date:  2015-05-01       Impact factor: 14.819

Review 5.  Macrophages: The Road Less Traveled, Changing Anticancer Therapy.

Authors:  Jennifer L Guerriero
Journal:  Trends Mol Med       Date:  2018-04-11       Impact factor: 11.951

6.  An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression.

Authors:  Miriam Walter; Elina Simanovich; Vera Brod; Nitza Lahat; Haim Bitterman; Michal A Rahat
Journal:  Oncoimmunology       Date:  2015-08-28       Impact factor: 8.110

7.  STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Authors:  Lekh N Dahal; Lang Dou; Khiyam Hussain; Rena Liu; Alexander Earley; Kerry L Cox; Salome Murinello; Ian Tracy; Francesco Forconi; Andrew J Steele; Patrick J Duriez; Diego Gomez-Nicola; Jessica L Teeling; Martin J Glennie; Mark S Cragg; Stephen A Beers
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

Review 8.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

9.  IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcγRI.

Authors:  Jennifer F A Swisher; Devin A Haddad; Anna G McGrath; Gunther H Boekhoudt; Gerald M Feldman
Journal:  MAbs       Date:  2014       Impact factor: 5.857

10.  Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Authors:  Martin Skarzynski; Carsten U Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E Marti; Katherine R Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.